The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Biosimilars & Follow-on-Biologics Market Research Report 2024
Synopsis
The global Biosimilars & Follow-on-Biologics market was valued at US$ 22490 million in 2023 and is anticipated to reach US$ 52070 million by 2030, witnessing a CAGR of 15.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biosimilars & Follow-on-Biologics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilars & Follow-on-Biologics.
Report Scope
The Biosimilars & Follow-on-Biologics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilars & Follow-on-Biologics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilars & Follow-on-Biologics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Synthon Pharmaceuticals
Teva Pharmaceutical Industries
LG Life Sciences
Celltrion
Biocon
Hospira
Merck Group
Biogen idec, Inc.
Genentech (Roche Group)
Segment by Type
Human Growth Hormone
Erythropoietin
Monoclonal Antibodies
Insulin
Interferon
Granulocyte-Colony Stimulating Factor
Peptide
Others
Segment by Application
Blood Disorders
Oncology Diseases
Chronic and Autoimmune Diseases
Growth Hormone Deficiencies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilars & Follow-on-Biologics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Biosimilars & Follow-on-Biologics market was valued at US$ 22490 million in 2023 and is anticipated to reach US$ 52070 million by 2030, witnessing a CAGR of 15.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Biosimilars & Follow-on-Biologics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Biosimilars & Follow-on-Biologics.
Report Scope
The Biosimilars & Follow-on-Biologics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Biosimilars & Follow-on-Biologics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Biosimilars & Follow-on-Biologics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Synthon Pharmaceuticals
Teva Pharmaceutical Industries
LG Life Sciences
Celltrion
Biocon
Hospira
Merck Group
Biogen idec, Inc.
Genentech (Roche Group)
Segment by Type
Human Growth Hormone
Erythropoietin
Monoclonal Antibodies
Insulin
Interferon
Granulocyte-Colony Stimulating Factor
Peptide
Others
Segment by Application
Blood Disorders
Oncology Diseases
Chronic and Autoimmune Diseases
Growth Hormone Deficiencies
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Biosimilars & Follow-on-Biologics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Biosimilars & Follow-on-Biologics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Human Growth Hormone
1.2.3 Erythropoietin
1.2.4 Monoclonal Antibodies
1.2.5 Insulin
1.2.6 Interferon
1.2.7 Granulocyte-Colony Stimulating Factor
1.2.8 Peptide
1.2.9 Others
1.3 Market by Application
1.3.1 Global Biosimilars & Follow-on-Biologics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Blood Disorders
1.3.3 Oncology Diseases
1.3.4 Chronic and Autoimmune Diseases
1.3.5 Growth Hormone Deficiencies
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Biosimilars & Follow-on-Biologics Market Perspective (2019-2030)
2.2 Biosimilars & Follow-on-Biologics Growth Trends by Region
2.2.1 Global Biosimilars & Follow-on-Biologics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Biosimilars & Follow-on-Biologics Historic Market Size by Region (2019-2024)
2.2.3 Biosimilars & Follow-on-Biologics Forecasted Market Size by Region (2025-2030)
2.3 Biosimilars & Follow-on-Biologics Market Dynamics
2.3.1 Biosimilars & Follow-on-Biologics Industry Trends
2.3.2 Biosimilars & Follow-on-Biologics Market Drivers
2.3.3 Biosimilars & Follow-on-Biologics Market Challenges
2.3.4 Biosimilars & Follow-on-Biologics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Biosimilars & Follow-on-Biologics Players by Revenue
3.1.1 Global Top Biosimilars & Follow-on-Biologics Players by Revenue (2019-2024)
3.1.2 Global Biosimilars & Follow-on-Biologics Revenue Market Share by Players (2019-2024)
3.2 Global Biosimilars & Follow-on-Biologics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Biosimilars & Follow-on-Biologics Revenue
3.4 Global Biosimilars & Follow-on-Biologics Market Concentration Ratio
3.4.1 Global Biosimilars & Follow-on-Biologics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Biosimilars & Follow-on-Biologics Revenue in 2023
3.5 Biosimilars & Follow-on-Biologics Key Players Head office and Area Served
3.6 Key Players Biosimilars & Follow-on-Biologics Product Solution and Service
3.7 Date of Enter into Biosimilars & Follow-on-Biologics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Biosimilars & Follow-on-Biologics Breakdown Data by Type
4.1 Global Biosimilars & Follow-on-Biologics Historic Market Size by Type (2019-2024)
4.2 Global Biosimilars & Follow-on-Biologics Forecasted Market Size by Type (2025-2030)
5 Biosimilars & Follow-on-Biologics Breakdown Data by Application
5.1 Global Biosimilars & Follow-on-Biologics Historic Market Size by Application (2019-2024)
5.2 Global Biosimilars & Follow-on-Biologics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Biosimilars & Follow-on-Biologics Market Size (2019-2030)
6.2 North America Biosimilars & Follow-on-Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Biosimilars & Follow-on-Biologics Market Size by Country (2019-2024)
6.4 North America Biosimilars & Follow-on-Biologics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Biosimilars & Follow-on-Biologics Market Size (2019-2030)
7.2 Europe Biosimilars & Follow-on-Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Biosimilars & Follow-on-Biologics Market Size by Country (2019-2024)
7.4 Europe Biosimilars & Follow-on-Biologics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Biosimilars & Follow-on-Biologics Market Size (2019-2030)
8.2 Asia-Pacific Biosimilars & Follow-on-Biologics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Biosimilars & Follow-on-Biologics Market Size by Region (2019-2024)
8.4 Asia-Pacific Biosimilars & Follow-on-Biologics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Biosimilars & Follow-on-Biologics Market Size (2019-2030)
9.2 Latin America Biosimilars & Follow-on-Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Biosimilars & Follow-on-Biologics Market Size by Country (2019-2024)
9.4 Latin America Biosimilars & Follow-on-Biologics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Biosimilars & Follow-on-Biologics Market Size (2019-2030)
10.2 Middle East & Africa Biosimilars & Follow-on-Biologics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Biosimilars & Follow-on-Biologics Market Size by Country (2019-2024)
10.4 Middle East & Africa Biosimilars & Follow-on-Biologics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Detail
11.1.2 Novartis Business Overview
11.1.3 Novartis Biosimilars & Follow-on-Biologics Introduction
11.1.4 Novartis Revenue in Biosimilars & Follow-on-Biologics Business (2019-2024)
11.1.5 Novartis Recent Development
11.2 Synthon Pharmaceuticals
11.2.1 Synthon Pharmaceuticals Company Detail
11.2.2 Synthon Pharmaceuticals Business Overview
11.2.3 Synthon Pharmaceuticals Biosimilars & Follow-on-Biologics Introduction
11.2.4 Synthon Pharmaceuticals Revenue in Biosimilars & Follow-on-Biologics Business (2019-2024)
11.2.5 Synthon Pharmaceuticals Recent Development
11.3 Teva Pharmaceutical Industries
11.3.1 Teva Pharmaceutical Industries Company Detail
11.3.2 Teva Pharmaceutical Industries Business Overview
11.3.3 Teva Pharmaceutical Industries Biosimilars & Follow-on-Biologics Introduction
11.3.4 Teva Pharmaceutical Industries Revenue in Biosimilars & Follow-on-Biologics Business (2019-2024)
11.3.5 Teva Pharmaceutical Industries Recent Development
11.4 LG Life Sciences
11.4.1 LG Life Sciences Company Detail
11.4.2 LG Life Sciences Business Overview
11.4.3 LG Life Sciences Biosimilars & Follow-on-Biologics Introduction
11.4.4 LG Life Sciences Revenue in Biosimilars & Follow-on-Biologics Business (2019-2024)
11.4.5 LG Life Sciences Recent Development
11.5 Celltrion
11.5.1 Celltrion Company Detail
11.5.2 Celltrion Business Overview
11.5.3 Celltrion Biosimilars & Follow-on-Biologics Introduction
11.5.4 Celltrion Revenue in Biosimilars & Follow-on-Biologics Business (2019-2024)
11.5.5 Celltrion Recent Development
11.6 Biocon
11.6.1 Biocon Company Detail
11.6.2 Biocon Business Overview
11.6.3 Biocon Biosimilars & Follow-on-Biologics Introduction
11.6.4 Biocon Revenue in Biosimilars & Follow-on-Biologics Business (2019-2024)
11.6.5 Biocon Recent Development
11.7 Hospira
11.7.1 Hospira Company Detail
11.7.2 Hospira Business Overview
11.7.3 Hospira Biosimilars & Follow-on-Biologics Introduction
11.7.4 Hospira Revenue in Biosimilars & Follow-on-Biologics Business (2019-2024)
11.7.5 Hospira Recent Development
11.8 Merck Group
11.8.1 Merck Group Company Detail
11.8.2 Merck Group Business Overview
11.8.3 Merck Group Biosimilars & Follow-on-Biologics Introduction
11.8.4 Merck Group Revenue in Biosimilars & Follow-on-Biologics Business (2019-2024)
11.8.5 Merck Group Recent Development
11.9 Biogen idec, Inc.
11.9.1 Biogen idec, Inc. Company Detail
11.9.2 Biogen idec, Inc. Business Overview
11.9.3 Biogen idec, Inc. Biosimilars & Follow-on-Biologics Introduction
11.9.4 Biogen idec, Inc. Revenue in Biosimilars & Follow-on-Biologics Business (2019-2024)
11.9.5 Biogen idec, Inc. Recent Development
11.10 Genentech (Roche Group)
11.10.1 Genentech (Roche Group) Company Detail
11.10.2 Genentech (Roche Group) Business Overview
11.10.3 Genentech (Roche Group) Biosimilars & Follow-on-Biologics Introduction
11.10.4 Genentech (Roche Group) Revenue in Biosimilars & Follow-on-Biologics Business (2019-2024)
11.10.5 Genentech (Roche Group) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
